Company intelligence / Profile preview

SunWay Biotech

Taipei City, Taipei City, Taiwansunway.cc ↗

Ownership: Private
Development stage: Other

Overview

SunWay Biotech has commercialized proprietary fermented red yeast rice extract ANKASCIN® 568-R—clinically studied for cholesterol, blood sugar, blood pressure management, and Alzheimer’s support—and Vigiis® 101-LAB probiotic ingredient for immune modulation and digestive health. ANKASCIN® 568-R has been accepted as a New Dietary Ingredient by the US FDA in 2015; its efficacy and safety are supported by over a decade of research including animal models and clinical studies.

Therapeutic areas: NeurologyGastroenterologyEndocrinologyImmunologyCardiovascular
Modalities: Live biotherapeutic product therapyMicrobial therapyFermentation-derived natural products
Industry: Non-Drug Biotech

Partnerships

Gnosis by Lesaffre (for joint launch of ANKASCIN/MenaQ7 metabolic supplement)

Beyond the preview

Go deeper on SunWay Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SunWay Biotech.

Explore the full profile